tirzepatide and vision eyesight The NAION signal observed with semaglutide continues to generate discussion. A new hypothesis suggests Vision loss: GLP-1 drugs like

It supports increased insulin release and reduces the speed of food digestion, serving as an efficient method for reducing appetite and caloric intake, thus standing out as a preferred option for weight loss injections in the community

It is important to approach emerging data with appropriate caution

Individuals should be insulin nave and should receive stable dose(s) of any of the following oral non-insulin glucose-lowering medications: metformin, dipeptidyl peptidase 4 (DPP4) inhibitors, sodium-glucose cotransporter 2 inhibitors, and/or alpha-glucosidase inhibitors

Other factors include smaller tub sizes and greater competition between brands